AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3 ...Middle East

At week 24, upadacitinib met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV)1 At week 52, the percent reduction from baseline in F-VASI was numerically...

Hence then, the article about abbvie announces upadacitinib rinvoq met the primary endpoint in phase 2 clinical trial of vitiligo as program advances to phase 3 was published today ( Thursday 12/10/2023 - 12:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3 )

Also on site :

• The World Cup cicada: India’s rare insect on a four-year clock
• Hungary sets condition for Ukraine’s EU accession bid
• US launches global crackdown on ‘birth tourism’